Page 346 of 346: studies 3,451 to 3,458 of 3,458, newest first. Back to the MDMA overview
Vincent Joralemon preprint
As psychedelic-assisted therapies advance through the FDA approval pipeline, the question of who will pay for them is moving from academic to urgent. Experts project that MDMA-assisted therapy for PTSD will cost upwards of $11,000-$12,000 per course of treatment-a price tag that, absent insurance, places these therapies out of reach for many of the patients most likely to benefit. This essay...
Baneet Gill
Background: Alcohol use disorder (AUD) is a serious condition that affects millions worldwide and can have devastating and far-reaching health, social and economic consequences. Current treatment rates, which refer to the percentage of the total population living with AUD receiving treatment, remain low. The treatments that do exist, such as medications and behavioural treatments, are not...
Eduardo Ekman Schenberg preprint
Between April and October 2024, expert bodies in two countries reached strikingly opposite conclusions about the therapeutic use of 3,4-methylenedioxymethamphetamine (MDMA). On the one hand, the Food and Drug Administration in the USA rejected a formal New Drug Application from a specific drug sponsor, Lykos Therapeutics, for Post-Traumatic Stress Disorder (PTSD). The decision was surprising to...
Mark A. Michaels preprint
This client-authored, autoethnographic case study documents a 10-week course of collaborative therapy integrating EMDR, ketamine, MDMA, psilocybin, creative expression, and AI-assisted reflection and writing. Drawing on affect theory, mentalization, earned secure attachment, and Dabrowski's theory of positive disintegration, the paper analyzes how recognition of core affects, rupture-and-repair...
Michael Palmieri preprint
Psychedelic-assisted therapy is advancing rapidly toward clinical legitimacy in the United States. The Food and Drug Administration has granted Breakthrough Therapy designations to psilocybin and MDMA, several states have established regulated access frameworks, and major research institutions have invested hundreds of millions of dollars in psychedelic science. Yet the legal infrastructure...
Michael Palmieri preprint
American informed consent doctrine rests on an unexamined premise: the stable-agent assumption—that the patient who authorizes a medical intervention and the patient who experiences its consequences share a continuous evaluative framework. Materiality doctrine presupposes this continuity; causation doctrine embeds it; capacity doctrine assumes it. For most of modern medical practice, the...
Minsu Yoo, Sofia Sakopoulos
Recent scientific findings spanning the past two decades have prompted a reevaluation of psychedelics, including psilocybin, LSD, and MDMA, as potent tools for mental health treatment. While these substances were historically associated with countercultural movements, concerns and excitement arise as they become commercialized. Based on in-depth interviews of relevant stakeholders of the scene,...
Research Square Sean M. Viña preprint
Abstract Background: Due to increasing cultural and legal acceptance of psychedelics, there is a need to understand their potential influence on formal mental health care. This paper examines the connection between psychedelics, distress, and treatment utilization. Are psychedelic users less likely to use formal mental health care? Methods This study tests the relationship between psychedelics...